Wanbury Limited — Updates, 20-12-2024: Press Release

Wanbury Limited's manufacturing facility in Tanuku, Andhra Pradesh successfully underwent an ANVISA inspection conducted by Brazil's Health Regulatory Agency. The inspection took place over four days, concluding with zero observations, underscoring the facility's strict adherence to current Good Manufacturing Practices (cGMP). This achievement is particularly significant as it follows a similar inspection by the US FDA in June 2024, which also resulted in no observations. The company anticipates receiving a GMP compliance certificate, which is expected to boost its global business growth. Wanbury is a key player in the production of Metformin HCl and Sertraline APIs, with additional APIs in the final stages of development, reinforcing the management's commitment to quality and regulatory standards. Positive outlook ahead as these validations strengthen the company's market position.